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Objective. To develop simple, practical criteria for clinical diagnosis of fibromyalgia that are suitable for use in primary
and specialty care and that do not require a tender point examination, and to provide a severity scale for characteristic
fibromyalgia symptoms.
Methods. We performed a multicenter study of 829 previously diagnosed fibromyalgia patients and controls using
physician physical and interview examinations, including a widespread pain index (WPI), a measure of the number of
painful body regions. Random forest and recursive partitioning analyses were used to guide the development of a case
definition of fibromyalgia, to develop criteria, and to construct a symptom severity (SS) scale.
Results. Approximately 25% of fibromyalgia patients did not satisfy the American College of Rheumatology (ACR) 1990
classification criteria at the time of the study. The most important diagnostic variables were WPI and categorical scales
for cognitive symptoms, unrefreshed sleep, fatigue, and number of somatic symptoms. The categorical scales were
summed to create an SS scale. We combined the SS scale and the WPI to recommend a new case definition of fibromyalgia:
(WPI >7 AND SS >5) OR (WPI 3–6 AND SS >9).
Conclusion. This simple clinical case definition of fibromyalgia correctly classifies 88.1% of cases classified by the ACR
classification criteria, and does not require a physical or tender point examination. The SS scale enables assessment of
fibromyalgia symptom severity in persons with current or previous fibromyalgia, and in those to whom the criteria have
not been applied. It will be especially useful in the longitudinal evaluation of patients with marked symptom variability.
INTRODUCTION
The introduction of the American College of Rheumatol-
ogy (ACR) fibromyalgia classification criteria 20 years ago
began an era of increased recognition of the syndrome (1).
The criteria required tenderness on pressure (tender
points) in at least 11 of 18 specified sites and the presence
of widespread pain for diagnosis. Widespread pain was
defined as axial pain, left- and right-sided pain, and upper
and lower segment pain.
Over time, a series of objections to the ACR classification
criteria developed, some practical and some philosophi-
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cal. First, it became increasingly clear that the tender point
count was rarely performed in primary care where most
fibromyalgia diagnoses occurred, and when performed,
was performed incorrectly (2). Many physicians did not
know how to examine for tender points and some simply
refused to do so (3). Consequently, fibromyalgia diagnosis
in practice has often been a symptom-based diagnosis.
Second, the importance of symptoms that had not been
considered by the ACR Multicenter Criteria Committee
became increasingly known and appreciated as key fibro-
myalgia features: for example, fatigue, cognitive symp-
toms, and the extent of somatic symptoms (4–7). In addi-
tion, a number of fibromyalgia experts believed that tender
points obscured important considerations and erroneously
linked the disorder to peripheral muscle abnormality (8).
Finally, some physicians considered that fibromyalgia was
a spectrum disorder and was not well served by dichoto-
mous criteria (9).
There was still another important problem with fibro-
myalgia diagnosis. Patients who improved or whose symp-
toms and tender points decreased could fail to satisfy the
ACR 1990 classification definition. It was not clear how to
categorize or assess these patients. In addition, the ACR
classification criteria set such a high bar for diagnosis that
there was little variation in symptoms among fibromyalgia
patients. These two considerations suggested the need for
a broad-based severity scale that could differentiate among
patients according to the level of fibromyalgia symptoms.
With all of these considerations in mind, we conducted
a multicenter study of patients with a diagnosis of fibro-
myalgia and a control group of rheumatic disease patients
with noninflammatory disorders to address the issues of
fibromyalgia diagnosis and symptom severity. The objec-
tives of this study were: 1) to identify non–tender point
diagnostic criteria for fibromyalgia; these criteria are not
meant to replace the ACR classification criteria, but to
represent an alternative method of diagnosis; 2) to inte-
grate severity scale–based symptoms in these new clinical
criteria, built on the characteristic features of fibromyalgia;
these criteria should be suitable for use in primary care
and helpful in following patients longitudinally; and 3) to
develop a fibromyalgia symptom severity (SS) scale.
To accomplish these objectives, we employed a 2-stage
design. In the first stage, we collected an extensive set of
patient and physician variables from 514 patients and
controls, including an index of pain extent (widespread
pain index [WPI]) and characteristic fibromyalgia symp-
toms. From the resultant data, models were developed for
the surrogate classification criteria, diagnostic criteria, and
a severity scale. In the second stage, 315 additional pa-
tients and controls were assessed by physicians with a
reduced set of variables in a physician questionnaire for-
mat that could be reduced to a single page suitable for
primary care use. The purpose of the phase 2 study was to
see if a shortened, practical physician questionnaire
would work as well in categorizing fibromyalgia as the
longer, more detailed phase 1 assessments. Thus, we pri-
marily report phase 1 data except for comparisons of clas-
sification rates and severity variables. Survey criteria,
based on patient self-report, will be the subject of a sepa-
rate report.
SUBJECTS AND METHODS
Study subjects and physicians. We recruited study phy-
sicians by selecting randomly from a list of 113 rheuma-
tologists who were members of the ACR and who indi-
cated an interest in participating in the study after an
e-mail solicitation. We also included 5 physicians with
known fibromyalgia expertise selected from the authors
(FW, DJC, MAF, DLG, ASK, PM, ASR, IJR, JBW).
Participating physicians had to be certain that they
would see 10 fibromyalgia patients and 10 noninflamma-
tory controls within a 4-month period. They had to be
experienced with fibromyalgia patients and the fibromyal-
gia tender point examination. All of the physicians com-
pleted a short instructional questionnaire on the Internet
and satisfactorily completed a brief examination on study
requirements and methods. We required that the physi-
cian, not an assistant, complete physician assessment
forms, and that patient forms could only be completed by
the patient.
We required the fibromyalgia study patients to have a
previous diagnosis of fibromyalgia. They were enrolled as
they appeared in the clinic for usual care (not by being
recalled) and without consideration of current diagnosis,
severity, or other characteristics. Fibromyalgia subjects
must have been diagnosed with fibromyalgia by the same
examining rheumatologist prior to the date of study assess-
ment. Patients diagnosed with fibromyalgia could have
been diagnosed on clinical grounds or by the ACR classi-
fication criteria (10). It was not a requirement of diagnosis
to have satisfied the ACR classification criteria. Of the 30
physicians contributing valid patients to phase 1 of the
study, 6 used only clinical diagnosis, 9 used only the ACR
classification criteria diagnosis, and 15 diagnosed some
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patients using clinical methods and some patients using
the ACR methods. Among the expert physicians, 4 used
clinical diagnosis, 4 used the ACR classification criteria
diagnosis, and 2 used both methods.
Control subjects were patients with noninflammatory
painful disorders such as degenerative neck and back pain
syndromes or regional disorders, osteoarthritis, tendonitis,
or similar disorders who had not been diagnosed previ-
ously as having fibromyalgia and who were of the same sex
and were no more than 10 years younger or 10 years older
than the fibromyalgia case. As with the fibromyalgia pa-
tients, the control subjects must have had a prior control
diagnosis. Patients with any inflammatory rheumatic dis-
order (e.g., rheumatoid arthritis), active cancer, fractures,
defined neuropathic causes of pain, or other nonrheumatic
causes for pain were excluded from the study.
In phase 1, we enrolled 610 patients from 32 referring
physicians between December 2, 2008, and April 30, 2009.
We excluded 96 patients (15.7%) for one or more protocol
violations. Two physicians enrolled fewer than 10 pa-
tients, 1 and 5 patients each, and their patients were ex-
cluded because of insufficient site enrollments. We also
excluded subjects for invalid control diagnoses (n  12)
and for failure to match fibromyalgia patients with con-
trols of the same sex within 10 years of age by sex (n  96)
by the time of study closure. After exclusions, there were
514 subjects (mean 17 and median 20 per center). From the
group of physician participants there were 10 “experts,”
defined as having published on fibromyalgia in the medi-
cal literature.
Study variables: phase 1. We instructed study sites to
have patients complete their forms before seeing the phy-
sician. Physicians were instructed not to look at the pa-
tient forms. Physicians’ staff was asked to check each
patient’s form for completeness and request completion of
missing items before the patient left the clinic.
Patient variables: phase 1. Patients were asked to indi-
cate in which of 19 body areas they had pain during the
last week. These areas were those previously described as
part of the Regional Pain Scale (renamed here as the WPI)
(11). We also analyzed the WPI as a categorical variable,
with categories 0, 1, 2, and 3 for values of 0, 1–3, 4–6, and
7 of the WPI, respectively. The categories were deter-
mined by study analyses (see below).
Patients completed 7 categorical scales for symptoms
over the past week that were scored as: 0  no problem;
1  slight or mild problems, generally mild or intermit-
tent; 2  moderate, considerable problems, often present
and/or at a moderate level; and 3  severe, pervasive,
continuous, life-disturbing problems. Symptoms were as-
sessed using the following words: pain, fatigue, trouble
with sleep, trouble with anxiety or depression, problems
awaking unrefreshed, and overall severity of your arthritis
or fibromyalgia problem. In addition, patients completed 4
visual analog scales that were scored as 0–10. The scale
questions and anchors were 1) severity of pain over the last
week, with anchors from no pain to severe pain; 2) how
much of a problem has fatigue or tiredness been for you
over the past week?, with anchors from fatigue is no prob-
lem to fatigue is a major problem; 3) how much of a
problem has sleep (i.e., resting at night) been for you in the
past week?, with anchors from sleep is no problem to sleep
is a major problem; and 4) how much of a problem has
waking up unrefreshed been for you in the last week?, with
anchors from waking up unrefreshed is no problem to
waking up unrefreshed is a major problem. Patients also
completed the Health Assessment Questionnaire II func-
tional disability scale (12). Patients indicated the number
of medications they used in the last month to help control
pain, and reported the extent of morning stiffness.
We also asked patients to indicate which of the follow-
ing symptoms they experienced in the last 3 months:
blurred vision or problems focusing; dry eyes; ringing in
ears; hearing difficulties; mouth sores; dry mouth; loss of
or change in taste; headache; dizziness; fever; chest pain;
shortness of breath; wheezing (asthma); loss of appetite;
nausea; heartburn; indigestion or belching; pain or dis-
comfort in the upper abdomen (stomach); liver problems;
pain or cramps in the lower abdomen (colon); diarrhea
(frequent, explosive watery bowel movements, severe);
constipation; black or tarry stools (not from iron); vomit-
ing; joint pain; joint swelling; low back pain; muscle pain;
neck pain; weakness of muscles; tiredness (fatigue); de-
pression; insomnia; nervousness (anxiety); seizures or
convulsions; trouble thinking or remembering; easy bruis-
ing; hives or welts; itching; rash; loss of hair; red, white,
and blue skin color changes in fingers on exposure to cold
or with emotional upset; sun sensitivity (unusual skin
reaction, not sunburn); yellow skin or eyes (jaundice);
fluid-filled blisters; numbness/tingling/burning; swelling
of the hands, legs, feet, or ankles (not due to arthritis);
irritable bowel syndrome; faintness; frequent urination;
painful urination; pain, fullness, or discomfort in the blad-
der region; sensitivity to bright lights, loud noises, or
odors; fatigue severe enough to limit daily activity; tender
lymph nodes; or frequent sore throats. We summed the
positive replies to create a 0–56 count of somatic symp-
toms scale.
Physician variables: phase 1. Physicians were asked
not to look at the forms completed by the patient. Physi-
cians indicated their certainty of the prior diagnosis on a
0–10 scale (0  very uncertain, 10  very certain). They
performed the ACR tender point count (0–18) (1) and
completed the same painful body region scale as their
patients did. They completed categorical scales for pain,
fatigue, sleep disturbance, cognitive symptoms, waking
unrefreshed, and overall (global) severity using the same
categorical scoring as the patients did. Physicians also
indicated if the patients had the following symptoms:
muscle pain, irritable bowel syndrome, fatigue, cognitive
problems, muscle weakness, headache, pain/cramps in the
abdomen, paresthesias, dizziness, sleep problem, depres-
sion, constipation, diarrhea, interstitial cystitis, anxiety,
and muscle tenderness.
We then provided the physicians a list of symptoms for
reference purposes and asked them to categorize the pa-
tients as having few or no somatic symptoms, a moderate
number of symptoms, or a great deal of symptoms. The
reference list consisted of: muscle pain, irritable bowel
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syndrome, fatigue/tiredness, thinking or remembering
problem, muscle weakness, headache, pain/cramps in the
abdomen, numbness/tingling, dizziness, insomnia, de-
pression, constipation, pain in the upper abdomen, nausea,
nervousness, chest pain, blurred vision, fever, diarrhea,
dry mouth, itching, wheezing, Raynaud’s phenomenon,
hives/welts, ringing in ears, vomiting, heartburn, oral ul-
cers, loss of/change in taste, seizures, dry eyes, shortness
of breath, loss of appetite, rash, sun sensitivity, hearing
difficulties, easy bruising, hair loss, frequent urination,
painful urination, and bladder spasms.
Based on the study results described below, we created
an SS scale by summing the 0–3 scores of somatic symp-
toms, waking unrefreshed, cognition, and fatigue into a
0–12 scale.
Phase 2 study and variables. The methods and rules for
physician and patient recruitment were the same for the
second phase, except that the authors with known fibro-
myalgia expertise were not recruited. In addition, patients
did not complete questionnaires. At the time of study
closure, 315 valid patients had been enrolled. The phase 2
form was simplified and completed only by the physician.
It contained the following items: a categorical WPI and a
question about widespread pain. Physicians were pro-
vided with a list of the widespread pain regions (scored as
0–3, 4–6, 7–10, or 11), but could not score the individ-
ual regions. Physicians performed and recorded a tender
point examination; indicated the presence or absence of
muscle pain, muscle tenderness, and irritable bowel syn-
drome; and provided a rating of the extent of somatic
symptoms (few or no symptoms, a moderate number of
symptoms, or a great deal of symptoms). For reference, a
list of 41 symptoms was supplied on the questionnaire.
Finally, we included categorical scales for sleep distur-
bance, unrefreshed sleep, cognitive problems, and fatigue,
with scoring as described above.
Statistical methods. On completion, study forms were
faxed to the National Data Bank for Rheumatic Diseases,
Wichita, Kansa, for processing. They were reviewed for
missing data, and if such data were found, the examining
physician was contacted immediately for corrections, if
possible. Missing patient data and physician data that
were not correctable within one week were left as missing.
Missing data were rare: in phase 1, 81.7% of patients had
no missing data, 12.8% had 1 missing data point, and
1.6% had 3–8 missing data points.
In phase 1 analyses, we considered 3 groups of classifier
variables: a short set of variables, an intermediate set, and
a complete set. The short set included the WPI and cate-
gorical scales for pain, fatigue, sleep disturbance, mood,
cognitive problems, somatic symptoms, and unrefreshed
sleep. The intermediate set included all of the variables in
the short set plus all of the individual somatic symptoms.
The complete set included all of the study variables. We
anticipated that, because of the need for simplicity, the
criteria and severity scales would probably come from the
short set. We analyzed the intermediate set under the
consideration that the individual symptoms might also be
important. The complete set allowed us to compare the 3
sets as to their classifying value and to understand what
might be lost in shortening the set of variables.
Comparisons between groups used t-tests, regression ana-
lyses with dummy variables, and chi-square tests, as indi-
cated. Spearman’s coefficients were used for correlation
analyses. Data were analyzed using Stata, version 10.1
(StataCorp), and the R statistical package, version 2.81.
Random forest analysis was used to determine variable
importance and “out-of-bag” error rates (10,11) using the R
statistical package. The out-of-bag error rate is a robust
measure of misclassification error. Variable importance is
described by the mean decrease in accuracy criterion or
the Gini Index, and it represents a ranking of variables in
terms of their importance as predictors. The mean de-
crease in accuracy is thought to be a better measure: “. . .
the Gini Index reflects the overall goodness of fit, while the
predictive accuracy depends on how well the model actu-
ally predicts. The two are related, but they measure differ-
ent things. Breiman argues that the decrease in predictive
accuracy is the more direct, stable and meaningful indica-
tor of variable importance (personal communication)”
(13). Classification tree analysis used the rpart recursive
partitioning R analysis programs to determine preliminary
cut points for criteria variables (14). Figure 1 describes the
distribution of study variables using a probability density
function. The reader can think of the probability density
function as a “smoothed-out” version of a histogram.
Conflict of interest and ethics. Examining physicians
were each compensated $2,000 for their work in interview-
ing, examining, and completing study forms for 10 pa-
tients and 10 controls. The study authors received no
compensation. The study was approved by the Via Christi
Institutional Review Board.
RESULTS
Demographics. Physicians enrolled 258 valid patients
in phase 1 whose clinical diagnosis was fibromyalgia and
Figure 1. Distribution of key fibromyalgia (FM) variables in con-
trols and patients with current or prior FM (phase 1). VAS 
visual analog scale.
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256 who were control subjects. Fibromyalgia subjects were
slightly older than controls (mean  SD age 54.6  12.9
versus 52.3  12.2 years; P  0.035), but did not differ by
the percentage of males (8.2% versus 9.0%; P  0.732),
percentage of non-Hispanic whites (86.8% versus 85.9%;
P  0.770), or education level (mean  SD 14.2  2.1
versus 14.3  2.2 years; P  0.517).
Diagnosis and diagnostic methods. ACR classification
criteria were used in 63.6% of fibromyalgia diagnoses and
clinical diagnosis was used in 36.4% of fibromyalgia diag-
noses. At the time of the study examination, 74.5% of
patients who had been previously diagnosed with fibro-
myalgia satisfied the ACR classification criteria and 2.0%
of controls satisfied the ACR classification criteria. Based
on these data, we categorized patients into 3 groups based
on prior diagnosis and ACR classification criteria status:
196 patients (38.1%) with current fibromyalgia (ACR clas-
sification criteria positive, physician fibromyalgia diagno-
sis positive), 67 patients (13.0%) with prior fibromyalgia
(ACR classification criteria negative, physician fibromyal-
gia diagnosis positive), and 251 patients (48.1%) who were
neither current nor prior fibromyalgia patients (control
subjects) (Table 1). Using a 0–10 physician certainty of
prior diagnosis scale, the mean certainties were: fibromy-
algia 9.4, prior fibromyalgia 8.7, and control diagnosis 9.1.
Patients previously diagnosed by clinical criteria were
more likely to be classified as prior fibromyalgia (38.3%)
compared with patients previously diagnosed by the ACR
classification criteria (18.9%; P  0.001). The proportion
of patients who were controls or had prior or current
fibromyalgia did not differ between the group of 10 expert
physicians and the 20 clinical rheumatologists (P  0.640).
Characteristics of patients by fibromyalgia status.
There was a clear difference in clinical findings and symp-
tom severity among the groups, the current fibromyalgia
patients having the greatest symptom severity with prior
fibromyalgia generally occupying the severity scale mid-
point between current fibromyalgia and controls (Table 1).
However, for the count of patient-endorsed somatic symp-
toms, the physician somatic symptom scale, and the SS
scale, prior fibromyalgia patients had scores that were
somewhat closer to current fibromyalgia patients than to
control subjects. Figure 1 shows differences between
groups for key variables. The tender point count (Figure
1D) demonstrates the clearest distinction between groups,
followed by unrefreshed sleep (Figure 1C). Prior and cur-
rent fibromyalgia patients had similar distributions of so-
matic symptom counts (Figure 1B), while prior fibromyal-
gia had the WPI shifted somewhat to the left (Figure 1A).
Taken as a whole, these data show that approximately
25% of patients considered to have fibromyalgia by their
physicians do not satisfy ACR classification criteria for
fibromyalgia, and that they appear to have an intermediate
severity position between fibromyalgia patients and con-
trol subjects, except for somatic symptoms.
Misclassification rates and fibromyalgia classifiers. To
determine variables that best identify fibromyalgia and to
examine the predictive power of study variables without
the use of tender points, we divided the subjects into ACR







No. of patients (%) 196 (38.1) 67 (13.0) 251 (48.1)
Widespread pain index (0–19) 11.4  4.4 8.2  5.0 3.8  3.2
Physician widespread pain index (0–19) 11.4  4.1 7.2  3.9 3.3  2.5
Widespread pain, % patients 92.9 56.7 31.1
Widespread pain, % physicians 93.9 59.7 24.3
Tender point count (0–18) 15.9  2.3 7.9  4.1 2.5  3.0
ACR 1990 classification criteria positive, % patients 92.9 0.0 0.0
ACR 1990 classification criteria positive, % physicians 93.9 0.0 0.0
ACR 1990 classification criteria positive, % patients or
physicians
100.0 0.0 0.0
Physician global severity, categorical (0–3) 2.1 1.5 1.1
Patient global severity, categorical (0–3) 2.4 1.8 1.4
Patient symptom count (0–48) 22.9  8.8 18.2  8.4 9.7  8.4
Physician somatic symptoms (0–3) 2.3  0.7 1.9  0.7 1.2  0.5
HAQ-II score (0–3) 1.3  0.6 1.0  0.7 0.7  0.6
Patient VAS unrefreshed sleep (0–10) 7.3  2.7 5.2  3.4 3.1  3.0
Patient VAS sleep (0–10) 6.5  2.8 4.4  3.2 3.3  3.0
Patient VAS pain (0–10) 6.5  2.3 4.9  2.7 4.1  2.8
Patient VAS fatigue (0–10) 7.0  2.4 5.0  3.1 3.3  2.9
Symptom severity scale (0–12)† 8.0  2.6 6.0  2.6 3.3  2.2
No. of pain medications 3.3  2.3 2.5  1.4 1.9  1.9
* Values are the mean  SD unless otherwise indicated. ACR  American College of Rheumatology; HAQ-II  Health
Assessment Questionnaire II; VAS  visual analog scale.
† Sum of physician somatic symptoms, physician waking unrefreshed, physician cognition, and physician fatigue.
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classification criteria–positive (all patients satisfying the
ACR classification criteria) and ACR classification criteria–
negative cases (all controls satisfying the ACR criteria),
after excluding patients who physicians designated as hav-
ing fibromyalgia but who did not satisfy the ACR classifi-
cation criteria. We then used random forest analyses to
rank physician predictors of fibromyalgia by their impor-
tance and to obtain misclassification rates. We examined
the WPI as a continuous variable (0–19) and also after
splitting it into categories at 0, 1–3, 4–6, and 7. In these
analyses, we examined the complete set of variables, an
intermediate set, and a short set (Table 2).
Depending on the number of variables in the model
(variable group) and whether the WPI was used as a con-
tinuous or a categorical variable, physician study variables
misclassified fibromyalgia cases and controls at rates of
6.2–10.3% (Table 2). Figure 2A shows that the WPI and
muscle tenderness were the most important variables in
the classification of cases and noncases. These data pro-
vide an estimate of the lowest misclassification rates of
surrogate criteria obtainable under optimum data mining
conditions.
We next performed analyses to determine misclassifica-
tion rates when muscle variables (muscle pain, muscle
tenderness) and the WPI were removed from the models.
Removing all of the muscle variables and the WPI resulted
in a misclassification rate of 16.1% (Table 2). Using the
same intermediate model but keeping muscle pain re-
duced the error rate to 14.0%, whereas removing the WPI
but leaving all muscle pain and muscle tenderness vari-
ables resulted in a misclassification rate of 10.3%. Using
the short variable list (that never contains muscle pain or
muscle weakness), the misclassification rate was 18.4%.
These data show that misclassification rates obtainable
under optimum data mining conditions that do not con-
tain ACR classification criteria–related variables are be-
tween 16.1% and 18.4% (14.0% if muscle pain is al-
lowed).
Based on the information in Table 2, we selected the
variables contained in the intermediate WPI categorical
model (7.3% error rate) for further study because that
model represented the best practical model that contained
the WPI and muscle data (Table 2) and had the lowest
misclassification rate. Random forest analysis provides in-
formation on variable importance and misclassification
rates, but does not provide information about the optimum
cut points for study variables. We then applied recursive
partitioning to the data and determined that values of the
WPI 7 best identified fibromyalgia cases and values 6
best identified control cases according to their ACR clas-
sification criteria status.
In addition, in the comparison of ACR classification
criteria–positive versus ACR classification criteria–nega-
tive cases (excluding prior fibromyalgia), the correct clas-
sification rates for phase 1 ran between 89.0% and 92.6%,
with higher rates being obtained in phase 2 analyses.
When all of the patients were considered, WPI 7 per-
formed about as well (83.6%) as physician diagnosis
(84.1%) in the classification of fibromyalgia in phase 1,
again with improvement in the phase 2 data. There was
some gain obtained by including information about mus-
cle pain or muscle tenderness. Overall, these data show
that patients who satisfy the ACR classification criteria can
be identified with an acceptable rate of error by the use of
the WPI alone, and with very slightly better results if
muscle tenderness or muscle pain is assessed.
The SS scale and fibromyalgia diagnostic criteria. To
build and identify an alternative definition of fibromyalgia
and to create an SS scale, we turned back to the interme-
diate categorical model that excluded the WPI and muscle
variables (Table 2 and Figure 2B). From Figure 2B, we
identified 6 categorical rating scale variables that had high
importance levels (somatic symptoms, waking unre-
freshed, cognition, fatigue, sleep problems, and mood). As
shown in Table 3, these variables are strongly correlated
with the tender point count and the WPI. For comparison,
pain intensity, with correlation coefficients of 0.346 and
0.437, respectively, was less strongly correlated. We cre-
ated an SS scale by summing the 0–3 scores of somatic
symptoms, waking unrefreshed, cognition, and fatigue,
into a 0–12 scale.
When applied to study patients, using the ACR classifi-
Table 2. Random forest out-of-bag misclassification rates for physician and patient variable groups in the diagnosis of ACR















Complete 6.2 6.4 NA NA NA
Intermediate 6.4 7.3 16.1 14.0 10.3





* Prior fibromyalgia cases are excluded from the analysis. ACR  American College of Rheumatology; WPI  widespread pain index; complete group 
all study variables; NA  not applicable; intermediate group  short group variables plus all individual somatic symptoms; short group  WPI and
categorical scales for pain, fatigue, sleep disturbance, mood, cognitive problems, somatic symptoms, and unrefreshed sleep.
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cation criteria definition of fibromyalgia, the mean  SD
SS scale score for fibromyalgia was 8.0  2.6, for prior
fibromyalgia was 6.0  2.6, and for controls was 3.3  2.2
(Table 1). The SS scale was strongly correlated with the
WPI (0.733) and the tender point count (0.680), and was
the strongest correlate of WPI after the tender point count,
which was correlated with the WPI at 0.773 (Table 3). As
shown in Figure 3, the SS scale appropriately follows the
definitions of ACR classification criteria–positive fibromy-
algia, prior fibromyalgia, and non-fibromyalgia, suggesting
that it can categorize fibromyalgia symptom severity.
Fibromyalgia case definition: diagnostic criteria. We
used the SS scale and the WPI to recommend a new case
definition of fibromyalgia: (WPI 7 AND SS 5) OR (WPI
3–6 AND SS 9) (Table 4). This definition recognizes that
fibromyalgia is more than just a high WPI scale by requir-
ing an SS scale score 5, and recognizes that a high level
(SS 9) of symptoms should be sufficient for diagnosis,
provided that there is sufficient body pain. Using this
definition, 9.1% of controls would be diagnosed as having
fibromyalgia, 53.1% of prior fibromyalgia patients would
be diagnosed as having fibromyalgia, and 14.1% of ACR
classification criteria–positive cases would not be diag-
nosed as having fibromyalgia. Overall, the fibromyalgia
rate among all of the study subjects would increase from
38.1% to 45.5% using the recommended definition. As
shown in Table 5, using the ACR classification criteria as
the gold standard, the diagnostic criteria diagnose 82.6%
of cases correctly compared with the clinician’s correct
diagnosis rate of 84.1%.
We also used the SS scale to aid in the diagnosis of
Figure 2. A, Variable importance (physician variables) in distin-
guishing fibromyalgia from controls in intermediate detail physi-
cian evaluation by random forest analysis in phase 1, including
the widespread pain index (WPI) and muscle symptoms. B, Vari-
able importance (physician variables) in distinguishing fibromy-
algia from controls in intermediate detail physician evaluation in
phase 1 by random forest analysis, excluding the Regional Pain
Scale (WPI) and muscle symptoms. Other variables are present/
absent conditions. Variable importance is described by the mean
decrease in accuracy criterion or the Gini Index, and it represents
a ranking of variables in terms of their importance as predictors.
The Gini Index reflects the overall goodness of fit, while the
predictive accuracy depends on how well the model actually
predicts. The two are related, but they measure different things
(13). The mean decrease in accuracy is thought to be a better
measure. C  categorical scale; IBS  irritable bowel syndrome.







Tender point count 1.000 0.773
Widespread pain index 0.773 1.000
Symptom severity scale 0.680 0.733
Symptom severity scale* 0.672 0.713
Somatic symptoms† 0.631 0.683
Waking unrefreshed† 0.622 0.656
Cognition† 0.575 0.592
Fatigue† 0.548 0.604
Sleep problems 0.524 0.546
Mood 0.504 0.534
Pain 0.346 0.437
* Five-component symptom severity scale (includes mood).
† Component of 4-component symptom severity scale.
Figure 3. Distribution of severity scores using the American Col-
lege of Rheumatology (ACR) 1990 classification criteria definition
of fibromyalgia (FM) by category of FM diagnosis in phases 1 and
2. A symptom severity scale score 6 identifies patients satisfying
the new diagnostic criteria in 92.3% of cases.
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clinical fibromyalgia, because Figure 3 suggests that sever-
ity scale criteria might be applicable. A severity score 7
correctly classifies 92.3% of cases identified by the new
diagnostic criteria definition: (WPI 7 AND SS 5) OR
(WPI 3–6 AND SS 9). When applied to the ACR classi-
fication criteria, correct classification falls to 79.2%. This
Table 4. Fibromyalgia diagnostic criteria
Criteria
A patient satisfies diagnostic criteria for fibromyalgia if the following 3 conditions are met:
1) Widespread pain index (WPI) 7 and symptom severity (SS) scale score 5 or WPI 3–6 and SS scale score 9.
2) Symptoms have been present at a similar level for at least 3 months.
3) The patient does not have a disorder that would otherwise explain the pain.
Ascertainment
1) WPI: note the number areas in which the patient has had pain over the last week. In how many areas has the patient had
pain? Score will be between 0 and 19.
Shoulder girdle, left Hip (buttock, trochanter), left Jaw, left Upper back
Shoulder girdle, right Hip (buttock, trochanter), right Jaw, right Lower back
Upper arm, left Upper leg, left Chest Neck
Upper arm, right Upper leg, right Abdomen
Lower arm, left Lower leg, left
Lower arm, right Lower leg, right




For the each of the 3 symptoms above, indicate the level of severity over the past week using the following scale:
0  no problem
1  slight or mild problems, generally mild or intermittent
2  moderate, considerable problems, often present and/or at a moderate level
3  severe: pervasive, continuous, life-disturbing problems
Considering somatic symptoms in general, indicate whether the patient has:*
0  no symptoms
1  few symptoms
2  a moderate number of symptoms
3  a great deal of symptoms
The SS scale score is the sum of the severity of the 3 symptoms (fatigue, waking unrefreshed, cognitive symptoms) plus the
extent (severity) of somatic symptoms in general. The final score is between 0 and 12.
* Somatic symptoms that might be considered: muscle pain, irritable bowel syndrome, fatigue/tiredness, thinking or remembering problem, muscle
weakness, headache, pain/cramps in the abdomen, numbness/tingling, dizziness, insomnia, depression, constipation, pain in the upper abdomen,
nausea, nervousness, chest pain, blurred vision, fever, diarrhea, dry mouth, itching, wheezing, Raynaud’s phenomenon, hives/welts, ringing in ears,
vomiting, heartburn, oral ulcers, loss of/change in taste, seizures, dry eyes, shortness of breath, loss of appetite, rash, sun sensitivity, hearing
difficulties, easy bruising, hair loss, frequent urination, painful urination, and bladder spasms.
Table 5. Percentage of patients correctly classified according to ACR 1990 classification criteria status and
diagnostic criteria*
Comparison









ACR classification criteria positive, FM patients 74.0 75.6
Classifying patients according to ACR 1990
classification criteria status
ACR 1990 criteria vs. physician diagnosis 84.1
ACR 1990 criteria vs. WPI 7 89.0 83.6 92.3 87.9
ACR 1990 criteria vs. WPI 7 plus muscle pain 89.9 84.6 95.2 90.5
ACR 1990 criteria vs. WPI 7 plus muscle tenderness 92.6 87.4 95.2 90.5
FM diagnostic criteria
ACR 1990 classification criteria vs. diagnostic criteria
((WPI 7 AND SS 5) OR SS 9)
88.1 82.6 95.2 90.8
ACR 1990 classification criteria vs. categorical SS
scale (SS 7)
84.3 79.2 88.8 84.5
Diagnostic criteria ((WPI 7 AND SS 5) OR SS 9)
vs. categorical SS scale (SS 7)
92.3 89.2
* ACR  American College of Rheumatology; FM  fibromyalgia; WPI  widespread pain index; SS  symptom severity.
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falloff is to be expected, as the definition of fibromyalgia is
shifted in the new criteria definition. Using the newly
proposed categorical definition for fibromyalgia, the
mean  SD SS scale score for fibromyalgia was 8.5  2.0,
and for non-fibromyalgia was 2.9  1.6. Using the SS scale
score cutoff of 7, the mean  SD respective scores were
8.6  1.8 and 2.8  1.4.
Phase 2 validation. The ACR classification criteria were
used in 74.6% of fibromyalgia diagnoses. Among patients
diagnosed as having fibromyalgia, 76.0% met ACR classi-
fication criteria compared with 74.5% in the first phase of
the study. We categorized the 315 patients into 3 groups
based on prior diagnosis and current ACR classification
criteria status: 42.2% with current fibromyalgia, 13.3%
with prior fibromyalgia, and 44.4% who were neither cur-
rent nor prior fibromyalgia patients. The validation sample
was slightly different in the 2 phases (Figure 3), and cri-
teria to identify ACR classification criteria cases worked
slightly better in phase 2.
DISCUSSION
We are aware of the inherent problems in the diagnosis of
somatic syndromes that lack objective physical or labora-
tory features or well-characterized pathologic findings.
The utility of such diagnostic criteria is very dependent on
the clinical setting. The initial ACR fibromyalgia classifi-
cation criteria stipulated that chronic widespread pain
was present for 3 months and it was understood that no
other disease was thought by the examiner to be account-
ing for the chronic widespread pain. These ACR classifi-
cation criteria performed well in specialty clinics and
were very useful in providing some patient homogeneity
for clinical trials. However, they have not been widely
embraced in primary care.
The diagnostic criteria suggested here (Table 4) are not
meant to replace the ACR classification criteria. Instead,
they were designed to address certain realities. First, the
clinical diagnosis in primary care does not ordinarily in-
volve a tender point count or an adequately executed
tender count when performed. Second, the case definition
of fibromyalgia has changed somewhat with increasing
recognition of the importance of cognitive problems and
somatic symptoms, factors that were not even considered
in the 1990 ACR classification criteria.
In developing new diagnostic criteria, we identified 2
variables that best defined fibromyalgia and its symptom
spectrum: the WPI and the composite SS scale. The WPI,
which strongly correlated with the tender point count and
the SS scale, best identified patients diagnosed with the
ACR classification criteria. We also selected the SS scale, a
composite variable composed of physician-rated cognitive
problems, unrefreshed sleep, fatigue, and somatic symp-
tom count to measure fibromyalgia symptom severity. We
used the WPI and the SS scale together to define fibromy-
algia diagnostic criteria: (WPI 7 AND SS 5) OR (WPI
3–6 AND SS 9). We also used the SS scale alone to
provide a measure of fibromyalgia symptom severity. In
many respects, these criteria are similar in concept to
those proposed by Yunus et al in 1981 (15). These authors
allowed fewer tender points in the presence of many
symptoms, and they stressed the importance of symptoms.
One of the important findings of the current study was
that approximately 25% of diagnosed fibromyalgia pa-
tients in both phases of the study did not satisfy the ACR
classification criteria, although they were considered to
have fibromyalgia by their physicians. Neither the ACR
classification criteria nor the diagnostic criteria suggested
here provide a solution for this classification dilemma. It
arises because fibromyalgia diagnosis is based on severity
assessments. The loss of a tender point or a painful region
for any reason, including improvement, can result in fail-
ing to meet classification or diagnostic criteria. Practically,
the conundrum involves patients who have fibromyalgia
but who do not meet criteria versus patients who do not
have fibromyalgia because they do not meet criteria. In this
respect, fibromyalgia differs from rheumatoid arthritis or
systemic lupus erythematosus, illnesses that do not in-
volve diagnosis based on symptom severity, where pa-
tients continue to have their condition even though they
may subsequently not meet diagnostic criteria.
We suggest the use of the SS scale to quantify fibromy-
algia symptom severity as a workable solution to this prob-
lem. As shown in Figure 3, the distribution of SS scale
scores defines the 3 diagnostic categories and provides
measurement of fibromyalgia symptom severity to patients
who do and do not currently satisfy ACR fibromyalgia
criteria. Practically, patients who have satisfied the ACR
classification or diagnostic criteria at one time can be
followed with the symptom scale, thereby linking current
status to previous diagnosis.
In creating the SS scale we chose not to use the mood
variable, although it had importance in Figures 2A and B.
We chose not to include mood because we judged mood
difficult to assess and because it might be a resultant
feature rather than a primary feature of the illness. Al-
though we omitted mood, it was correlated with the SS
scale at 0.725 and with the components of the SS scale as
follows: cognition 0.625, somatic symptoms 0.621, waking
unrefreshed 0.619, and fatigue 0.612. In addition, as
shown in Table 3, a 5-component SS scale that included
mood did not perform as well as a 4-component scale.
Unrefreshed sleep was a better measure than sleep distur-
bance and we recommend its use in the SS scale. However,
in sensitivity analyses, it provided marginally better dif-
ferentiating power; we suggest that either scale can be
used, although unrefreshed sleep is better. Of the binary
variables, irritable bowel syndrome, abdominal pain, and
headache had variable importance. However, they added
no power to correct classification and we did not include
them in the diagnostic criteria.
In addition, in developing criteria for clinical diagnosis
we were cognizant of the need to make the diagnostic
criteria simple enough and easy enough so that they would
actually be used in clinical practice. To that end, we used
simple categorical scales for the symptom scale and com-
pressed the WPI to a similar categorical scale. None of this
guarantees that the scales will be used appropriately, but it
is easy enough to use them appropriately, and the knowl-
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edge that these are key factors will increase recognition of
such important symptoms.
In designing this study, we were concerned that a simple
questionnaire would lose too much information. There-
fore, we used a complex series of questions and evaluation
in phase 1. Based on the results in Table 2, which showed
little gain from the complete data sets, we collapsed the
questionnaire to categorical scales and changed the format
to a form that could be used in the clinic. Results from
phase 2 in Table 5 suggest that the criteria would work
satisfactorily in the final format, which is included in
Table 4.
Readers might wonder: why is it so difficult to make new
fibromyalgia criteria? The central problem in fibromyalgia
criteria is the absence of a gold standard or case definition.
The ACR classification criteria, rightly criticized for circu-
larity (16), created a de facto case definition by imposing
the 11 tender point rules on top of a crude definition of
widespread pain (17). Subsequent studies as well as the
data of this study showed the importance of (improved)
quantitative measures of body pain (18–22), and of the key
variables that comprise the SS scale in characterizing fi-
bromyalgia. The shift in the conceptualization of fibromy-
algia that occurred in the clinic and in research studies,
however, provided no clear case definition. In the current
study, we derived an empirical case definition from the
variable importance analyses. The diagnostic criteria and
SS scale we have proposed shift the fibromyalgia defini-
tion somewhat toward important symptoms: first, the cri-
teria can be satisfied by a high level of symptoms if the
WPI score is not high enough; second, fibromyalgia symp-
toms are accorded appropriate importance by the provi-
sion of the SS scale.
The suggested diagnostic criteria create a small discor-
dance between the older ACR classification criteria case
definition and the current definition that we have pro-
posed. However, it is clear that the ACR classification
criteria are unable to provide a useful classification for the
25% of fibromyalgia cases we identified as prior fibromy-
algia, something that can be somewhat ameliorated
through the use of the SS scale. In addition, it should be
remembered that physician diagnosis only correctly clas-
sified 84.1% of cases, while the proposed diagnostic cri-
teria, even with shift of definition, identified 82.6% of
patients correctly (Table 5).
We envision the use of the diagnostic criteria in the
following ways: following a diagnosis of fibromyalgia by
ACR classification or diagnostic criteria, the results of the
SS scale can document baseline symptom severity. Should
the patient subsequently not satisfy ACR classification or
diagnostic criteria, the SS scale can be used to measure
current symptom severity status and change in status with-
out the contradiction of having a diagnosis of fibromyalgia
but not satisfying fibromyalgia criteria at the same time. Of
course, the SS scale can also be used at any time regardless
of diagnostic status. The SS scale alone provides some
diagnostic information, but does not include the WPI. It
provides information as to symptom severity and it allows
fibromyalgia to be seen as part of a continuum, as some
have suggested. The criteria and severity scale also pro-
vide room for those who are uncomfortable with the fibro-
myalgia concept, as they can simply report the WPI and
the SS scale.
Physicians who are used to the ACR classification crite-
ria may be uncomfortable with the absence of a physical
examination criterion in the new diagnostic criteria. How-
ever, 98.7% of the patients in the study satisfying the
diagnostic criteria had a least 1 tender point and 96.3%
had 3 or more tender points. Even though the new criteria
do not include a physical examination criterion, all of the
patients being diagnosed should have a physical examina-
tion, which may include examination of tender point sites.
We would like to point out that implicit in the 1990 ACR
classification criteria was the requirement that clinical
examination and clinical judgment had excluded other
causes of chronic widespread pain, and such an exclusion
is also implicit in the proposed diagnostic criteria. It is
important for physicians to perform an appropriate clini-
cal assessment to exclude other diagnoses, and/or to iden-
tify potential coexisting rheumatic diseases that may re-
quire treatment themselves.
Although not a study requirement for enrollment, all of
the patients with fibromyalgia diagnosed by physicians
had symptoms for at least 3 months. However, the time-
frame for the physician assessment of WPI and the SS scale
was 1 week. We used this timeframe to more accurately
determine the level of symptoms. The new diagnostic cri-
teria require that patients diagnosed as having fibromyal-
gia will have had a similar level of symptoms for at least 3
months, in agreement with the ACR classification criteria.
Although we collected data directly from patients as
well as data from physicians, patient data did not work as
well in correct classification as physician data (Table 2).
The best misclassification rate obtainable with patient data
was 12.7% compared with 6.2% with physician data. This
difference is related to the fact that it is the physician and
not the patient who makes the diagnosis.
This study has a number of limitations. Although our
goal was to develop simple, practical criteria for clinical
diagnosis of fibromyalgia that are suitable for use in pri-
mary and specialty care, we did not study the performance
of these criteria in primary care. We recommend that a
followup study in the primary care setting be accom-
plished. We also did not test the criteria among those with
other rheumatic conditions, and we recommend that this
be done in the future, too. The patient population should
include those with relevant differential diagnoses (i.e.,
other rheumatic conditions) to determine the rate of mis-
classification that may occur. If, as we expect, the diagnos-
tic criteria perform well, it seems possible that the ACR
classification criteria might be withdrawn.
In summary, we have developed a case definition and
diagnostic criteria for fibromyalgia: (WPI 7 AND SS 5)
OR (WPI 3–6 AND SS 9). This simple clinical case def-
inition of fibromyalgia correctly classifies 88.1% of cases
classified by the ACR classification criteria, and does not
require a physical or tender point examination. The SS
scale enables assessment of fibromyalgia symptom severity
in persons with current or previous fibromyalgia, and in
those to whom the criteria have not been applied. It will be
especially useful in the longitudinal evaluation of patients
with marked symptom variability.
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